More on UCBJY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $138.03 |
|
|||
| Open | $141.82 | ||||
| 52 Wk High | $46.25 | ||||
| 52 Wk Low | $32.74 | ||||
| Day High | $141.90 | ||||
| Day Low | $139.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 40,476 | ||||
- UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.
- UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg
- UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS
- UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
- Barclays Downgrades UCB (UCB:BB) (UCBJY) to Equalweight
- UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
- BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
- Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
- Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis
- UCB to acquire Neurona Therapeutics for up to $1.15 billion
Entities mentioned with UCBJY
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Show More...
